Theses›Healthcare & bio

Healthcare & bio

What hospitals, labs and drug makers buy.

  • 16 theses
  • 11 bear
Early78913101112413141516Closing256 Early78913101112413141516Closing256
Fig. 1Where the bets sit: windows from Early to Shut, left to right; each plot's area is the market's size by 2035. A double outline is a bull call, a single one a bear call, a dashed one a thesis with no call written yet. 3 not yet sized are drawn small.
The marketsnumbered as the plan
  1. 1Biocomputing
    • Bear
    • Early
    • $11B
    • Support 78
     Living-neuron / organoid biocomputing is a real and accelerating research field, but as an investment it does not clear the gate today.
  2. 2Brain-computer interfaces
    • Closing
    • $12B
    • Support 61
     In BCI, venture value accrues to the neural-interface silicon layer (modular/chiplet ASICs, mature-node CMOS plus analog front-ends), not the full-stack clinical device
  3. 3Molecular biosensing
    • Early
    • $5.5B
    • Support 61
     Molecular biosensing: chip-scale detection of proteins, enzymes and biomarkers across transduction physics
  4. 4Metabolic wearables
    • Bear
    • Early
    • $2.1B
    • Support 61
     A full-stack metabolic wearable with a hard optical-sensing moat reaches venture scale by 2028, where the chip-supplier and OEM-feature models cannot
  5. 5Biophotonics
    • Bear
    • Closing
    • $1.6B
    • Support 61
     In biophotonics the venture-differentiated layer is the photonic-IC / source / detector silicon inside the instrument, not the clinical device; value migrates forward to the regulated device and assay incumbent, so capture is mostly public/incumbent through 2029
  6. 6Implantable neural electrodes
    • Bear
    • Closing
    • $1.3B
    • Support 61
     The open BCI question is whether an implantable electrode-materials team (graphene, soft conducting polymers, thin-film arrays) holds licensable IP that every implant builder must buy
  7. 7Non-invasive brain measurement
    • Bear
    • Early
    • $24B
     Non-invasive brain measurement: a new-modality cohort (OPM-MEG, functional NIRS, transcranial ultrasound, portable MRI) chasing a market the three imaging incumbents already own
  8. 8Neuromodulation
    • Bear
    • Early
    • $18B
     Venture-backed neuromodulation exits stay capped at the strategic tuck-in band (~$0.5-0.65B) through 2029, because four incumbents own the channel and copy the differentiator
  9. 9Light-controlled therapeutics
    • Early
    • $15B
     Does light become a paid therapeutic control layer beyond dermatology once the first optogenetic, photoimmunotherapy and endoscopic light-drug approvals arrive (2027-2029)?
  10. 10Pharma analytical instrumentation
    • Bear
    • Early
    • $3.6B
     Two European entrants arrived in one quarter selling MEASUREMENT into a pharmaceutical workflow rather than a drug into a patient.
  11. 11Organoid safety testing
    • Bear
    • Early
    • $3.5B
     Organoid safety testing: human tissue replacing the animal toxicity study
  12. 12Perovskite radiation detection
    • Bear
    • Early
    • $2.7B
     Perovskite semiconductors win a durable niche in radiation / X-ray / particle detection where their stopping power and low-cost solution processing beat incumbents.
  13. 13Photopharmacology in scope-reachable tissue
    • Bear
    • Early
    • $96M
     Light-switchable small molecules, not optogenetic gene therapy, win the first light-controlled therapies in tissue a scope or catheter can light (bladder, gut, airway, skin) by 2034, and the molecule owner captures it through pharma licensing
  14. 14Connectomics tooling
    • Bear
    • Early
     Does the neural-data-acquisition + connectomics-tooling layer become a fundable horizontal picks-and-shovels market under brain-algorithm AI, or do the application companies integrate it away?
  15. 15Diagnostics and health sensing
    • Early
     Liquid biopsies, real-time sensors and GLP-1-class drugs do not reduce system-level healthcare cost, they migrate it from acute treatment of today's cheap-and-fast killers into a longer tail of frailty, dementia and chronic disease
  16. 16Transcranial focused ultrasound
    • Early
     Transcranial ultrasound is the only non-surgical modality that can reach deep brain targets at millimetre scale, and the same hardware can stimulate and read.